Opioid use during pregnancy can have significant implications for both the mother and the developing fetus.

Opioids are a class of drugs that include prescription painkillers (e.g., oxycodone, hydrocodone) and illicit substances like heroin. Opioid use during pregnancy is associated with an increased risk of complications, including an elevated risk of preterm birth, low birth weight, intrauterine growth restriction, and stillbirth. Opioids are substances that can cross the placenta, exposing the developing fetus to the drugs. This exposure can potentially lead to various adverse effects on fetal development, including an increased risk of birth defects. One of the most well-known consequences of maternal opioid use during pregnancy is the risk of neonatal abstinence syndrome (NAS). NAS occurs when the newborn experiences withdrawal symptoms after birth due to exposure to opioids in the womb. Maternal opioid use during pregnancy can also have long-term effects on the child's development. These effects may include cognitive and behavioral problems, as well as an increased risk of substance use disorders later in life.

Pain management and concerns

Opioid usage is common among pregnant women and is on the rise.[1] Opioid drugs are used for various reasons during pregnancy, with pain being a frequent issue. Conditions like pelvic and lower back pain, occurring in around 68 to 72% of pregnancies, are commonly treated with these medications.[1][2][3] Moreover, other sources of pain like muscle aches, migraines, and joint pain are commonly reported during pregnancy.[1][4]

However, when it comes to chronic pain, guidelines from the American Pain Society recommend discussing the advantages and disadvantages of chronic opioid therapy with women and, if possible, limiting or avoiding opioid use during pregnancy due to potential risks to the fetus.[1][5] Even though there is evidence suggesting harmful impacts on fetal development caused by prescription opioids,[6][7][8][9] research conducted in both Europe and the United States consistently shows elevated levels of prescription opioid use during pregnancy, whether it's for medical reasons or due to opioid dependency.[1] It's important to note that prescription opioids encompass a range of medications, and the potential effects on the fetus may differ between different medications within the same drug class.[1]

Complications

Opioids can cross both the placental and blood-brain barriers, which poses risks to fetuses and newborns exposed to these drugs before birth. This exposure to opioids during pregnancy can lead to potential obstetric complications, including spontaneous abortion, abruption of the placenta, pre-eclampsia, prelabor rupture of membranes, and fetal death.[10][11] There are also adverse outcomes in newborns associated with maternal opioid use during pregnancy, such as sudden infant death syndrome, being smaller than expected for their gestational age, preterm birth, lower birth weight, and reduced head size.[10][12] Neonatal abstinence syndrome is a commonly observed issue in newborns who were exposed to opioids before birth.

Birth defects

The use of opioids in the early stages of pregnancy is associated with an elevated risk of congenital anomalies. Specifically, there is a two-fold increased likelihood of certain birth defects, including congenital heart defects, gastroschisis, and neural tube defects.[10][9][6] The risk of preterm birth and neonatal complications is reduced to some extent when dextropropoxyphene or codeine is used in comparison to other opioid analgesics.[13][14]

Neurodevelopment

The potential impact on the neurodevelopment of infants exposed to opioids before birth is another significant concern. A recent meta-analysis revealed noteworthy deficiencies in cognitive, psychomotor, and behavioral abilities in infants and preschool-aged children who had experienced chronic intrauterine opioid exposure.[10] Children who experienced neonatal abstinence syndrome were notably more prone to hospitalizations due to cognitive impairments, communication, speech, or language disorders, autism spectrum disorder, and behavioral problems, particularly those concerning emotional control.[15][16]

Neonatal withdrawal

Neonatal abstinence syndrome occurs when newborns go through withdrawal from opiates and is linked to dysfunction in the central and autonomic nervous systems, the respiratory system, and the gastrointestinal tract.[13] Additionally, there is an elevated risk of neonatal abstinence syndrome associated with the medical use of certain opioid analgesics, such as tramadol, codeine, and propoxyphene.[13]

Management

Pregnant women with opioid use disorder have treatment options including methadone, naltrexone, or buprenorphine to decrease opioid usage and enhance treatment adherence.[17][18] Current guidelines suggest that methadone and buprenorphine are equally viable choices. Nevertheless, recent research suggests that buprenorphine may offer certain advantages over methadone.[19]

See also

References

  1. 1 2 3 4 5 6 Desai, Rishi; Brogly, Susan; Yazdy, Mahsa (2015-07-31). "Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature". Journal of Pediatric Genetics. Georg Thieme Verlag KG. 04 (2): 056–070. doi:10.1055/s-0035-1556740. ISSN 2146-4596. PMC 4795985. PMID 26998394.
  2. ↑ Wang, Shu-Ming; Dezinno, Peggy; Maranets, Inna; Berman, Michael R.; Caldwell-Andrews, Alison A.; Kain, Zeev N. (2004). "Low Back Pain During Pregnancy". Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health). 104 (1): 65–70. doi:10.1097/01.aog.0000129403.54061.0e. ISSN 0029-7844. PMID 15229002. S2CID 33447178.
  3. ↑ Mogren, Ingrid M.; Pohjanen, Anna I. (2005). "Low Back Pain and Pelvic Pain During Pregnancy". Spine. Ovid Technologies (Wolters Kluwer Health). 30 (8): 983–991. doi:10.1097/01.brs.0000158957.42198.8e. ISSN 0362-2436. PMID 15834344. S2CID 30924654.
  4. ↑ Bateman, Brian T.; Hernandez-Diaz, Sonia; Rathmell, James P.; Seeger, John D.; Doherty, Michael; Fischer, Michael A.; Huybrechts, Krista F. (2014-05-01). "Patterns of Opioid Utilization in Pregnancy in a Large Cohort of Commercial Insurance Beneficiaries in the United States". Anesthesiology. Ovid Technologies (Wolters Kluwer Health). 120 (5): 1216–1224. doi:10.1097/aln.0000000000000172. ISSN 0003-3022. PMC 3999216. PMID 24525628.
  5. ↑ Chou, Roger; Fanciullo, Gilbert J.; Fine, Perry G.; Adler, Jeremy A.; Ballantyne, Jane C.; Davies, Pamela; Donovan, Marilee I.; Fishbain, David A.; Foley, Kathy M.; Fudin, Jeffrey; Gilson, Aaron M.; Kelter, Alexander; Mauskop, Alexander; O'Connor, Patrick G.; Passik, Steven D.; Pasternak, Gavril W.; Portenoy, Russell K.; Rich, Ben A.; Roberts, Richard G.; Todd, Knox H.; Miaskowski, Christine (2009). "Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain". The Journal of Pain. Elsevier BV. 10 (2): 113–130.e22. doi:10.1016/j.jpain.2008.10.008. ISSN 1526-5900. PMC 4043401. PMID 19187889.
  6. 1 2 Broussard, Cheryl S.; Rasmussen, Sonja A.; Reefhuis, Jennita; Friedman, Jan M.; Jann, Michael W.; Riehle-Colarusso, Tiffany; Honein, Margaret A. (2011). "Maternal treatment with opioid analgesics and risk for birth defects". American Journal of Obstetrics and Gynecology. Elsevier BV. 204 (4): 314.e1–314.e11. doi:10.1016/j.ajog.2010.12.039. ISSN 0002-9378. PMID 21345403.
  7. ↑ MB, Bracken; TR, Holford (1981). "Exposure to prescribed drugs in pregnancy and association with congenital malformations". Obstetrics and Gynecology. Obstet Gynecol. 58 (3): 336–344. ISSN 0029-7844. PMID 7266953.
  8. ↑ Rothman, Kenneth J.; Fyler, Donald C.; Goldblatt, Allan; Kreidberg, Marshall B. (1979). "Exogenous hormones and other drug exposures of children with congenital heart disease". American Journal of Epidemiology. Oxford University Press (OUP). 109 (4): 433–439. doi:10.1093/oxfordjournals.aje.a112701. ISSN 1476-6256. PMID 443241.
  9. 1 2 Yazdy, Mahsa M.; Mitchell, Allen A.; Tinker, Sarah C.; Parker, Samantha E.; Werler, Martha M. (2013). "Periconceptional Use of Opioids and the Risk of Neural Tube Defects". Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health). 122 (4): 838–844. doi:10.1097/aog.0b013e3182a6643c. ISSN 0029-7844. PMC 4557737. PMID 24084542.
  10. 1 2 3 4 Lind, Jennifer N.; Interrante, Julia D.; Ailes, Elizabeth C.; Gilboa, Suzanne M.; Khan, Sara; Frey, Meghan T.; Dawson, April L.; Honein, Margaret A.; Dowling, Nicole F.; Razzaghi, Hilda; Creanga, Andreea A.; Broussard, Cheryl S. (2017-06-01). "Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review". Pediatrics. American Academy of Pediatrics (AAP). 139 (6). doi:10.1542/peds.2016-4131. ISSN 0031-4005. PMC 5561453. PMID 28562278.
  11. ↑ Finkelstein, N.B. Substance Abuse Treatment: Addressing the Specific Needs of Women. DIANE Publishing. p. 51. ISBN 978-1-4379-4397-9.
  12. ↑ Page, Kimberly; Murray-Krezan, Cristina; Leeman, Lawrence; Carmody, Mary; Stephen, Julia M.; Bakhireva, Ludmila N. (2022-01-06). "Prevalence of marijuana use in pregnant women with concurrent opioid use disorder or alcohol use in pregnancy". Addiction Science & Clinical Practice. Springer Science and Business Media LLC. 17 (1): 3. doi:10.1186/s13722-021-00285-z. ISSN 1940-0640. PMC 8734065. PMID 34991713.
  13. 1 2 3 Källén, Bengt; Borg, Natalia; Reis, Margareta (2013-10-10). "The Use of Central Nervous System Active Drugs During Pregnancy". Pharmaceuticals. MDPI AG. 6 (10): 1221–1286. doi:10.3390/ph6101221. ISSN 1424-8247. PMC 3817603. PMID 24275849.
  14. ↑ Källén, Bengt; Reis, Margareta (2012). "Neonatal Complications After Maternal Concomitant Use of SSRI and Other Central Nervous System Active Drugs During the Second or Third Trimester of Pregnancy". Journal of Clinical Psychopharmacology. Ovid Technologies (Wolters Kluwer Health). 32 (5): 608–614. doi:10.1097/jcp.0b013e3182668568. ISSN 0271-0749. PMID 22926593. S2CID 34350836.
  15. ↑ Chanal, Corinne; Mazurier, Evelyne; Doray, Bérénice (2022). "Use of Psychoactive Substances during the Perinatal Period: Guidelines for Interventions during the Perinatal Period from the French National College of Midwives". Journal of Midwifery & Women's Health. Wiley. 67 (S1): S17–S37. doi:10.1111/jmwh.13419. ISSN 1526-9523. PMID 36480661. S2CID 254477949.
  16. ↑ Uebel, Hannah; Wright, Ian M.; Burns, Lucy; Hilder, Lisa; Bajuk, Barbara; Breen, Courtney; Abdel-Latif, Mohamed E.; Feller, John M.; Falconer, Janet; Clews, Sarah; Eastwood, John; Oei, Ju Lee (2015-10-01). "Reasons for Rehospitalization in Children Who Had Neonatal Abstinence Syndrome". Pediatrics. American Academy of Pediatrics (AAP). 136 (4): 811–820. doi:10.1542/peds.2014-2767. ISSN 0031-4005. PMID 26371197.
  17. ↑ Tran, Tran H.; Griffin, Brooke L.; Stone, Rebecca H.; Vest, Kathleen M.; Todd, Timothy J. (2017). "Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women". Pharmacotherapy: The Journal of Human Pharmaoclogy and Drug Therapy. Wiley. 37 (7): 824–839. doi:10.1002/phar.1958. ISSN 0277-0008. PMID 28543191. S2CID 13772333.
  18. ↑ Jones, Hendrée E.; Deppen, Krisanna; Hudak, Mark L.; Leffert, Lisa; McClelland, Carol; Sahin, Leyla; Starer, Jacquelyn; Terplan, Mishka; Thorp, John M.; Walsh, James; Creanga, Andreea A. (2014). "Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers". American Journal of Obstetrics and Gynecology. Elsevier BV. 210 (4): 302–310. doi:10.1016/j.ajog.2013.10.010. ISSN 0002-9378. PMC 7213596. PMID 24120973.
  19. ↑ Rausgaard, Nete Lundager Klokker; Ibsen, Inge Olga; Jørgensen, Jan Stener; Lamont, Ronald Francis; Ravn, Pernille (2019-07-05). "Management and monitoring of opioid use in pregnancy" (PDF). Acta Obstetricia et Gynecologica Scandinavica. Wiley. 99 (1): 7–15. doi:10.1111/aogs.13677. ISSN 0001-6349. PMID 31197827. S2CID 189815978.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.